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Since the discovery of antimicrobial agents, ever-
evolving mechanisms of microbial resistance have 
been shaping the field of infectious diseases. Globally 
multidrug-resistant (MDR) Gram-negative bacilli 
causing nosocomial infections (notably in Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Enterobacter sp. and Acinetobacter 
baumannii) have become an important emerging threat.[1]
In South Africa (SA), carbapenem resistance is emerging in 
K.  pneumoniae and Enterobacter sp. while high levels of resistance 
to all antimicrobial classes are observed among P.  aeruginosa and 
A. baumannii.[2] A. baumannii is a common pathogen in intensive care 
units (ICUs).[3] The antimicrobial susceptibility patterns of isolates of 
bacteraemic A.  baumannii complex isolates over time in the public 
and private sectors in SA are shown in Figs 1A and 1B, respectively. 
Particularly striking is the decline in carbapenem susceptibility from 
35% in 2007 to only 17% in 2011 in the public sector. More than 
half the isolates in the private sector were resistant to carbapenems, 
but there was no clear downward trend. Inappropriate antibiotic 
prescription practices in ICUs in the public and private sectors in 
SA are common and associated with poor patient outcomes.[4] Both 
carbapenem resistance and inappropriate antibiotic use are associated 
with increased mortality in patients with Acinetobacter bacteraemia.[5-8] 
Many acinetobacteria and other MDR Gram-negative bacteria 
are only susceptible to colistin (polymyxin E). Colistin is not a 
registered medicine in SA, but it can be obtained via a Medicines 
and Related Substance Act, Section 21 application to the Medicines 
Control Council. The polymyxin group of antibiotics was discovered 
in the 1940s,[9,10] but their popularity soon faded due to reports of 
nephrotoxicity and the availability of safer antibiotics in the 1970s.[11] 
Important pharmacokinetic and pharmacodynamic data for colistin are 
lacking, which are necessary for safe and effective dosing, particularly 
in critically ill patients and those with impaired renal function.[12] No 
international consensus exists on the correct dose, and dosing units 
are not standardised. Package insert dosing instructions differ between 
manufacturers. An additional problem is that prescribing units differ 
between manufacturers, including mg for colistin base activity (CBA) 
and colistimethate sodium (CMS), and international units for CMS. 
This creates confusion among clinicians and complicates interpreting 
the available literature. The product accessed in SA (Colimycine) is 
labelled in international units. One million units (MU) of CMS is 
roughly equivalent to 80 mg of CMS and 30 mg of CBA.
Under-dosing of colistin increases the risk of the development of 
resistance and hetero-resistance, which is important as colistin is the 
last line of defence against MDR Gram-negative bacteria. Colistin 
resistance was first reported in the Czech Republic in 1999 and 
worldwide reports are accumulating at an alarming rate.[13] Eighteen 
of 132 (13.6%) bloodstream isolates of A. baumannii complex were 
resistant to colistin in Groote Schuur Hospital, SA, during 2011. 
Methods
We conducted a systematic review of the evidence for rational dosing 
of intravenous (IV) colistin, with a particular focus on patients who 
are critically ill or have renal impairment. English language, peer-
reviewed journal publications (predating April 2013) were identified 
by searching the PubMed database. The search terms included 
various combinations of the following keywords: polymyxins; 
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After reviewing the abstracts, relevant full-
text manuscripts were retrieved. Additional 
articles were identified by hand searching 
the references of articles obtained by the 
electronic search strategy. Finally, based on 
the evidence obtained, an IV colistin dosing 
guideline for the treatment of MDR Gram-
negative infections was developed, with a 
particular focus on critically ill patients. 
Results
Pharmacokinetic overview
Colistin is administered intravenously 
as the inactive pro-drug CMS, which is 
hydrolysed to active colistin.[14] In critically 
ill patients, colistin plasma concentrations 
peak seven hours after CMS administration. 
The half-lives of CMS and colistin are 2.3 
and 14.4 hours, respectively. [15] Distribution 
to cerebrospinal, pleural and synovial fluid is 
poor.[10] Unconverted CMS is predominantly 
eliminated by the kidneys, partly by 
tubular secretion. By contrast, colistin is 
predominantly cleared by unknown non-
renal mechanisms and undergoes extensive 
renal tubular reabsorption.[16]
Dose adjustment in renal failure
In patients with renal impairment the 
elimination of CMS is decreased and a 
greater fraction of the administered dose 
is converted to colistin,[17-19] necessitating a 
dose adjustment. Both CMS and colistin 
are efficiently cleared by venovenous 
haemofiltration[20] and haemodialysis.[17,21-22] 
Therefore, a supplemental dose of colistin 
needs to be given after dialysis and higher 
doses are required in patients undergoing 
venovenous haemofiltration. 
Loading doses
Drugs take 4 - 5 times their half-lives to reach 
target steady-state plasma concentrations. 
A loading dose is required in serious 
infections to rapidly achieve therapeutic 
concentrations. Critically ill patients with 
severe sepsis have significant capillary leak,[23-24] 
which increases the volume of distribution 
of colistin 4 - 15-fold.[25-26] The loading dose 
in critically ill patients is therefore higher 
than in less-ill patients.[15,17] It is important 
to note that the magnitude of the loading 
dose is not affected by renal impairment; 
only subsequent maintenance doses or dose 
intervals should be adjusted.
Pharmacokinetic-
pharmacodynamic relationships 
Colistin has no activity against Gram-positive 
bacteria and anaerobes,[10] but rapidly kills 
Gram-negative bacteria in a concentration-
dependent manner.[14,19,27] The bactericidal 
activity of colistin is partly due to its detergent 
effect on the bacterial cell membrane.[10,19,28] 
This disruptive effect on membrane integrity 
may account for the in vitro synergy observed 
with certain antimicrobials (e.g. rifampicin). [28] 
Murine studies showed that the most 
predictive index for antibacterial effect against 
P. aeruginosa and A. baumannii was the ratio 
of the area under the curve to the minimum 
inhibitory concentration (AUC/MIC).[29-30]
Extrapolating from murine AUC/MIC 
colistin data, Garonzik et al.[17] estimated 
that in humans a total colistin AUC/
MIC of 60 is the average achieved using 
currently recommended doses. This AUC/
MIC of 60 would be expected to result in 
a suboptimal pharmacodynamic effect of 
somewhere between stasis and 1  log10 kill 
for most susceptible bacteria. The authors 
acknowledge that there are limitations 
to their estimates as free concentrations 
of colistin were measured in the murine 
infection models[29-30] and there are no 
human data on the protein binding of 
colistin. Peak concentrations of at least 
4  mg/l (four times the MIC) were needed 
to eliminate P. aeruginosa in one study, but 
in critically ill patients this concentration 
was only reached with doses of 9  MU of 
CMS.[31] A recent in vitro study showed 
that the mutant prevention concentration 
(at which 90% of isolates tested were 
prevented from developing mutant strains) 
exceeds 128  mg/l,[32] a concentration not 
achievable with currently used doses. A 
high proportion of clinician-selected dosing 
regimens result in sub-therapeutic colistin 
concentrations. [12,15,17,26,31,33] Of particular 
concern is a recent study showing that it 
is not possible to reach the modest target 
Fig. 1. Susceptibility of A. baumannii complex blood isolates to selected antimicrobial agents at 
laboratory sites in South Africa, 2007 - 2011. (A) Five large public sector (2011 susceptibility data are 
based on provisional results);[2,43] and (B) eight private sector laboratory sites (personal communication, 
Colleen Bamford for the National Antibiotic Study Forum). 
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colistin AUC/MIC of 60 in patients with creatinine clearances 
>70 ml/ min without exceeding the upper limit daily dose of 10 MU 
CMS recommended in the package insert.[17]
Dosing interval
The recommended dosing intervals of colistin range between 6 and 
12 hours. The long half-life of colistin suggests that less frequent 
dosing intervals should be adequate. On theoretical grounds 
giving higher doses less frequently should result in higher peak 
concentrations and more effective bacterial eradication. However, 
extended dosing intervals may lead to periods of low colistin 
concentrations allowing for resistant subpopulations to occur 
within a microbial population susceptible to colistin (hetero-
resistance).[28-30,34] Small, uncontrolled studies report good efficacy, 
without significant renal toxicity, of high-dose CMS regimens 
given 12-hourly[35] or daily.[31] There are no randomised, controlled, 
clinical trials (RCTs) evaluating the efficacy and safety of once-, 
twice- and thrice-daily dosing of colistin.
Combination therapy
A strong theoretical basis exists for the use of colistin as part 
of combination antimicrobial therapy to maximise antimicrobial 
activity and to reduce the risk of the emergence of resistance, 
especially in patients with normal renal function or with bacterial 
MICs >1 mg/l. [10,17] As discussed above, currently used doses (9 MU 
CMS per day in divided doses) can neither achieve the modest 
target AUC/MIC of 60 in patients with normal renal function,[17] nor 
prevent the selection of resistant mutant subpopulations.[10,32] 
Many studies have proposed different colistin combination 
regimens. The most frequently studied are combinations of colistin 
with rifampicin or the carbapenems,[13] which both showed synergy 
in vitro.[36] Other in vitro studies report effective combinations 
with tigecycline, amikacin, fosfomycin, azithromycin, ceftazidime, 
minocycline and, surprisingly, the glycopeptides vancomycin and 
teicoplanin.[10,13] Combination with levofloxacin or tobramycin 
decreased the mutant selection window of colistin.[37] Some in 
vitro antibiotic combination studies demonstrated bactericidal 
activity even against colistin-resistant strains and others showed 
bactericidal activity at sub-MIC concentrations of colistin.[28] There 
is an urgent need for RCTs comparing the efficacy of different 
combinations of antimicrobial agents with colistin. One trial 
showed that the 30-day mortality rate of patients with serious 
MDR A. baumannii infections was not reduced by the addition of 
rifampicin to colistin, but the study was limited by the relatively low 
total daily dose of CMS (6 MU) used.[44]
Nephrotoxicity
In contrast to initial reports that colistin’s nephrotoxicity rates 
approached 50%, the majority of recent studies report much lower 
renal toxicity rates of 10 - 30%.[38] A local study found that the risk 
of nephrotoxicity of colistin (dosed at the relatively low total daily 
dose of 6 MU of CMS) was similar to that of tobramycin.[39] Colistin’s 
nephrotoxicity is dose-dependent and mostly mild and reversible. [25,38,40] 
One study showed that rates of nephrotoxicity were significantly 
higher in patients receiving daily maintenance doses greater than 
the equivalent of 12  MU of CMS in a 70  kg patient.[38] Colistin’s 
exact mechanism of nephrotoxicity is not established.[11,12,40,41] Patients 
with abnormal renal function at the start of colistin therapy have 
consistently been identified as being at high risk for nephrotoxic 
events.[28] General measures to limit colistin’s nephrotoxicity include 
regular monitoring of renal function with appropriate dose adjustment 
(especially with prolonged use), adequate hydration and limited use 
of concomitant nephrotoxic drugs. Therapeutic monitoring of CMS/
colistin concentrations is not commercially available.
Discussion
It is imperative that colistin is dosed appropriately to minimise 
the risk of resistance as it is a last-line agent against MDR Gram-
negative bacteria, and the pipeline of new drugs in development for 
these organisms is very small.[42] There are good theoretical grounds 
to suggest that colistin should be used in combination with other 
effective antibacterials, especially in patients with normal renal 
function and when treating bacteria with MICs >1 mg/l.[10,17] 
We used the information gleaned from our systematic review to 
develop simple recommendations for rational dosing (Table  1). A 
key study that informed our recommendations was conducted by 
Garonzik et al.,[17] who integrated population pharmacokinetic data 
with pharmacodynamic data in a model to estimate dosing in critically 
ill patients with a wide range of renal function (including those 
receiving renal replacement therapy). Even though the maintenance 
doses we recommend are higher than in the package insert of the 
currently used unregistered product in SA, these will still only result 
in concentrations that have suboptimal bacterial killing. Higher 
doses are likely to result in unacceptable rates of nephrotoxicity.[38] We 
suggest 12-hour dosing intervals in view of the long half-life of colistin 
(14 hours) and because of the theoretical benefit of the resulting 
higher peak concentrations, but, as discussed above, 8-hourly dosing 
is also acceptable. CMS is unstable in aqueous solutions, therefore it 
should be administered shortly after reconstitution.[10] All critically ill 
patients with severe sepsis, regardless of their renal function, require 
a loading dose of 9 - 12 MU of CMS to ensure the rapid attainment of 
Table 1. IV CMS dosing guideline for the treatment of MDR Gram-negative infections 
Dose Patient category Dosing suggestion
Loading Critically ill or severe sepsis 9 - 12 MU*
Maintenance eGFR >60 ml/min 4.5 MU 12-hourly
eGFR 30 - 60 ml/min 3 MU 12-hourly
eGFR 10 - 30 ml/min 2 MU 12-hourly 
eGFR <10 ml/min 1 MU 12-hourly
Intermittent haemodialysis 1 MU 12-hourly plus supplemental dose of 
1 MU after each episode of dialysis
Continuous renal replacement 4.5 MU 12-hourly†
IV = intravenous; CMS = colistimethate sodium; MDR = multidrug-resistant; eGFR = estimated glomerular filtration rate.
*Loading dose is calculated according to ideal body weight: 12 MU CMS for 70 kg and 9 MU for 55 kg patients.
†Garonzik et al.[17] recommend higher daily doses of 16 MU as both CMS and colistin are filtered during renal replacement therapy. 
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therapeutic concentrations. [15,17] The loading dose range in the table is 
based on ideal body weight. The loading dose should be administered 
intravenously over 1 - 2 hours, followed by the first maintenance dose 
after 12 hours.[15] Maintenance doses can be given as IV infusions over 
15  min.[26] In patients with an estimated glomerular filtration rate 
<60 ml/min, CMS dose adjustment is required. Twelve-hourly dosing 
is appropriate in patients with renal impairment, because only CMS, 
the inactive pro-drug, is subjected to renal elimination (not the active 
drug colistin). CMS doses equal to or even higher than the daily 
dose in patients with normal renal function are required in patients 
on continuous renal replacement therapy, because both CMS and 
colistin are removed.[17,22] Garonzik et al.[17] recommend a daily dose of 
16 MU of CMS in this setting. 
There is a clear need for further research on colistin, particularly 
to establish pharmacokinetic-pharmacodynamic relationships 
in humans. More RCTs need to be conducted to determine if 
combination therapy results in superior outcomes, and, if so, which 
combinations should be used. Finally, access to colistin needs to be 
made easier in SA, especially in the public sector where carbapenem 
resistance is increasing. 
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